NCT07923812: Effectiveness and Safety of Disease-Modifying Therapy for Alzheimer's Disease: A Multicenter Retrospective Study
Study Design & Technical Specifications
Sample Size / Cohort
3,000 Participants
Subject / Study Model
Human Clinical Cohort
Analytical Modalities
Primary Abstract & Repository Description
Source: ClinicalTrials.gov (NIH/NLM)Editorial Critique, Methodological Value & Reusability Guide
1. Scientific Context & Premise
Primary Premise (ClinicalTrials.gov (NIH/NLM)): "The goal of this multicenter retrospective observational study is to learn about the real-world safety and clinical effectiveness of disease-modifying therapy (DMT) in adults with mild cognitive impairment (MCI) due to Alzheimer's disease (AD) or AD dementia." Within Alzheimer's Disease (AD), this work examines NCT07923812, Observational / Cohort, RECRUITING, Disease-Modifying Therapy in relation to Aβ42/40, p-tau217, p-tau181, GFAP, NfL, and APOE ε4 genotype interactions. Authored by Fudan University.
2. Study Architecture & Findings
Study Architecture: Human Clinical Cohort (3,000 Participants) utilizing Clinical Trial Protocol, Observational / Cohort, Therapeutic Intervention. Key reported conclusion: "Researchers will retrospectively collect existing clinical data, including cognitive and neuropsychiatric assessments, imaging findings, biomarker results, DMT use, and safety information."
3. Secondary Analysis & Reusability
Secondary Analysis Applications: (1) Cross-referencing Clinical Trial Protocol, Observational / Cohort, Therapeutic Intervention variables (NCT07923812, Observational / Cohort, RECRUITING, Disease-Modifying Therapy) against open repositories in Alzheimer's Disease (AD); (2) Benchmarking feature distributions and effect sizes reported in "NCT07923812: Effectiveness and Safety of Disease-Modifying Therapy for Alzheimer"; (3) Informing cohort stratification and endpoint selection.
4. Methodological Caveats & Governance
Methodological Note: When integrating these Clinical Trial Protocol, Observational / Cohort, Therapeutic Intervention findings, account for cohort-specific inclusion criteria (3,000 Participants), potential site/instrument batch effects, and repository license terms (NLM Public Domain Open Registry).
Data Access, Reproducibility & Analysis Starter Guide
FAIR Open Science & Clinical Metadata Verification Protocol
Quick Data Access & Structured Export
Open the primary repository directly or download structured metadata (JSON / CSV) in one click.
This resource is indexed under FAIR (Findable, Accessible, Interoperable, and Reusable) open-science metadata standards, enabling programmatic cross-referencing across Europe PMC, Semantic Scholar, ClinicalTrials.gov, and CNS Open Data.
Programmatic Data Retrieval (Python Starter Code & Recommended SDKs)
Python Quickstart: Query Europe PMC & Semantic Scholar Metadata
# Fetch structured bibliographic & open-access data via Europe PMC REST API
import urllib.request
import urllib.parse
import json
query = "NCT07923812: Effectiveness and Safety of Disease-Modifying Therapy for Alzheimer"
url = f"https://www.ebi.ac.uk/europepmc/webservices/rest/search?query={urllib.parse.quote(query)}&format=json&resultType=core"
with urllib.request.urlopen(url, timeout=10) as response:
payload = json.loads(response.read().decode("utf-8"))
results = payload.get("resultList", {}).get("result", [])
if results:
record = results[0]
print("Title:", record.get("title"))
print("Journal / Source:", record.get("journalTitle") or record.get("bookOrReportDetails"))
print("Cited By Count:", record.get("citedByCount", 0))Standardized 4-Step Workflow & Governance Checklist
Standardized Acquisition & Preprocessing Workflow
1. Programmatic Metadata & Full-Text OA Retrieval
Query Europe PMC or Crossref REST APIs using the persistent DOI/URL to retrieve structured XML full text, supplementary tables, and grant links.
2. Study Design & Cohort Eligibility Screening
Extract sample size, inclusion/exclusion criteria, and primary outcome endpoints for systematic review (PRISMA) inclusion.
3. Data Availability & Supplementary Repository Linkage
Locate accession numbers (GEO, SRA, OpenNeuro, DANDI, Zenodo, Figshare) referenced in the Data Availability section.
4. Citation Graph & Replication Tracking
Monitor supporting and contrasting citations over time to verify whether key findings have been independently replicated.
Reproducibility & Governance Checklist
- Verify whether the source is a peer-reviewed journal publication or an unrefereed preprint before clinical citation.
- Check supplementary data licenses (CC-BY / CC0) when extracting figures or summary statistics for meta-analyses.
- Cross-reference NCT clinical trial identifiers when evaluating therapeutic efficacy or biomarker endpoints.
Tags & Modalities
Related Alzheimer's & Dementia Research & Datasets
Explore All DatasetsAgora Target Validation: INPP5D (inositol polyphosphate-5-phosphatase D) in Alzheimer’s Disease
This gene is a member of the inositol polyphosphate-5-phosphatase (INPP5) family and encodes a protein with an N-terminal SH2 domain, an inositol phosphatase domain, and two C-terminal protein interaction domains. Expression of this protein is restricted to hematopoietic cells where its movement from the cytosol to the...
OpenNeuro ds004504: Multimodal MRI & PET Repository for Early Alzheimer’s Disease and Mild Cognitive Impairment (BIDS)
An exceptional multimodal neuroimaging repository providing 3T structural MRI, resting-state fMRI, and [18F]Florbetapir Amyloid-PET scans from 180 subjects formatted strictly to BIDS standard. This open dataset serves as a benchmark resource for deep learning and diagnostic biomarker discovery in early Alzheimer's and MCI.
Agora Target Validation: NRN1 (neuritin 1) in Alzheimer’s Disease
This gene encodes a member of the neuritin family, and is expressed in postmitotic-differentiating neurons of the developmental nervous system and neuronal structures associated with plasticity in the adult. The expression of this gene can be induced by neural activity and neurotrophins. The encoded protein contains a ...
Agora Target Validation: BIN1 (bridging integrator 1) in Alzheimer’s Disease
This gene encodes several isoforms of a nucleocytoplasmic adaptor protein, one of which was initially identified as a MYC-interacting protein with features of a tumor suppressor. Isoforms that are expressed in the central nervous system may be involved in synaptic vesicle endocytosis and may interact with dynamin, syna...
Allen Brain Atlas: Multi-plane optical physiology during image change detection
Time series of behavioral variables and neural activity measured with multi-plane in vivo 2-photon imaging in mice performing a visual change detection task where mice were trained with image set A and tested with a novel image set B... Freely accessible open data product maintained by the Allen Institute for Brain Science.
Agora Target Validation: HTRA1 (HtrA serine peptidase 1) in Alzheimer’s Disease
This gene encodes a member of the trypsin family of serine proteases. This protein is a secreted enzyme that is proposed to regulate the availability of insulin-like growth factors (IGFs) by cleaving IGF-binding proteins. It has also been suggested to be a regulator of cell growth. Variations in the promoter region of ...
Active Clinical Trials & Pipeline in Alzheimer's & Dementia
View Clinical PipelineNCT07721467: Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin
NCT07779863: Acupressure as Long-term Intervention to Slow the Progression of Early/Mild Alzheimer's Disease
NCT07923812: Effectiveness and Safety of Disease-Modifying Therapy for Alzheimer's Disease: A Multicenter Retrospective Study
Related Data & Resources
Academic Research & Medical Information Disclaimer
This page provides structured scientific metadata, methodological critiques, and open-data reusability guidelines intended strictly for neuroscience researchers and data scientists. It does not constitute medical advice, clinical diagnosis, or treatment recommendations.
Was this resource helpful?
Help improve data curation by sharing your feedback.